{"disease":{"id":"iga-nephropathy-igan","name":"iga nephropathy igan"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06674577","title":"A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":476,"lead_sponsor_name":"Vera Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06819826","title":"A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Biocity Biopharmaceutics Co., Ltd.","has_results":false},{"nct_id":"NCT06676007","title":"A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Sichuan Provincial People's Hospital","has_results":false},{"nct_id":"NCT07098897","title":"To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"The Affiliated Hospital of Xuzhou Medical University","has_results":false},{"nct_id":"NCT04689074","title":"Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari","has_results":false},{"nct_id":"NCT07052981","title":"Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":124,"lead_sponsor_name":"Guixia Ding","has_results":false},{"nct_id":"NCT07474636","title":"Efficacy and Safety Study of HS-10542 for IgA Nephropathy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06670352","title":"Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Haisco Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT06687174","title":"Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Wuhan Createrna Science and Technology Co., Ltd","has_results":false},{"nct_id":"NCT06786338","title":"A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":38,"lead_sponsor_name":"Suzhou Sanegene Bio Inc.","has_results":false},{"nct_id":"NCT03841448","title":"A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT07056595","title":"Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Botkin Hospital","has_results":false},{"nct_id":"NCT07389499","title":"A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Grit Biotechnology","has_results":false},{"nct_id":"NCT07305974","title":"A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.","has_results":false},{"nct_id":"NCT07022574","title":"Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT07498335","title":"Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07445906","title":"A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.","has_results":false},{"nct_id":"NCT05125068","title":"Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"Eledon Pharmaceuticals","has_results":false},{"nct_id":"NCT06676579","title":"Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":16,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07535138","title":"Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Air Force Military Medical University, China","has_results":false},{"nct_id":"NCT06926985","title":"An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Jieyang People's Hospital","has_results":false}],"total":21},"guidelines":[],"source":"Drug Landscape verified database"}